Livzon Pharmaceutical Group Inc.
000513
Classement en actions
#4689
Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and... Livzon Pharmaceutical Group Inc., headquartered in Zhuhai, China, and established in 1985, is a biopharmaceutical enterprise operating across the entire spectrum of pharmaceutical activities, from research and development to manufacturing and commercialization. The company's operations encompass a diverse range of finished drug products, active pharmaceutical ingredients (APIs), and chemical intermediates, primarily serving the Chinese market while also engaging in international exports. Its pharmaceutical portfolio includes treatments such as Ilaprazole enteric coated tablets for duodenal ulcers and reflux esophagitis, Laprazole sodium injection for managing peptic ulcer bleeding, Leuprorelin Acetate Microspheres for injection, and Urofollitropin injection for anovulation and fertility support. Livzon also produces Perospirone Hydrochloride for schizophrenia, Anti-viral Granules targeting upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, spontaneous sweating, and vertigo, and provides supportive care for lung and stomach cancer patients. Beyond therapeutic drugs, Livzon Pharmaceutical Group develops and distributes a variety of diagnostic reagents. These include kits for detecting IgM/IgG antibodies to coronavirus, nucleic acid tests for human immunodeficiency virus type 1, antinuclear antibody test kits, interferon-gamma release assay kits, and rapid tests for mycoplasma pneumoniae IgM antibodies. The company's extensive offerings further extend to biochemical drugs, microbiological preparations, biologics, traditional Chinese medicine formulations, pharmaceutical raw materials, and antibiotics.
Prix de l'action
$3.90
Capitalisation boursière
$3.17B
Changement (1 jour)
-3.49%
Changement (1 an)
-25.88%
Pays
CN
Échange Livzon Pharmaceutical Group Inc. (000513)
Catégorie
Healthcare
Bénéfices pour Livzon Pharmaceutical Group Inc. (000513)
Bénéfices en Jun 2026 TTM : $353.39M
Selon les derniers rapports financiers de Livzon Pharmaceutical Group Inc., les bénéfices actuels de l'entreprise sont de $353.39M. En 2024, l'entreprise a réalisé un bénéfice de $384.45M, une augmentation par rapport à celui de 2023 qui était de $336.60M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Livzon Pharmaceutical Group Inc. de 2001 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $353.39M | -13.61% |
| 2025 | $409.07M | 6.40% |
| 2024 | $384.45M | 14.22% |
| 2023 | $336.60M | -0.37% |
| 2022 | $337.86M | -4.38% |
| 2021 | $353.32M | -7.28% |
| 2020 | $381.07M | 53.60% |
| 2019 | $248.09M | 20.46% |
| 2018 | $205.95M | -76.59% |
| 2017 | $879.92M | 507.84% |
| 2016 | $144.76M | 16.35% |
| 2015 | $124.42M | 18.19% |
| 2014 | $105.27M | 1.52% |
| 2013 | $103.69M | 15.39% |
| 2012 | $89.85M | 22.30% |
| 2011 | $73.47M | -9.13% |
| 2010 | $80.85M | -6.35% |
| 2009 | $86.33M | 457.58% |
| 2008 | $15.48M | -81.76% |
| 2007 | $84.91M | 200.91% |
| 2006 | $28.22M | 72.44% |
| 2005 | $16.36M | -12.46% |
| 2004 | $18.69M | -1.91% |
| 2003 | $19.06M | 40.37% |
| 2002 | $13.58M | 11.75% |
| 2001 | $12.15M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $3.62B | 923.75% |
DE
|
|
| $3.40B | 863.51% |
DE
|
|
| $1.72B | 387.73% |
JP
|
|
| $930.30M | 163.25% |
CH
|
|
| $1.69B | 378.97% |
IN
|
